Results 31 to 40 of about 743,600 (215)

Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy.

PLoS ONE, 2019
Radiological biomarkers have been reported for multiple system atrophy and progressive supranuclear palsy, but serum/plasma biomarkers for each disorder have not been established.
Akio Mori, Kei-Ichi Ishikawa, Shinji Saiki, Taku Hatano, Yutaka Oji, Ayami Okuzumi, Motoki Fujimaki, Takahiro Koinuma, Shin-Ichi Ueno, Yoko Imamichi, Nobutaka Hattori   +10 more
doaj   +1 more source

Comparison of gait in progressive supranuclear palsy, Parkinson’s disease and healthy older adults

BMC Neurology, 2012
Background Progressive supranuclear palsy and Parkinson’s disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to analyze the gait of people with progressive supranuclear palsy (
Egerton Thorlene, Williams David R, Iansek Robert   +2 more
doaj   +1 more source

Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR-PSP). [PDF]

Mov Disord Clin Pract
Background Progressive supranuclear palsy (PSP) is a rare and devastating tauopathy with limited global data. Given India's large population, genetic diversity, and clinical heterogeneity, large multicenter datasets are crucial to enrich global understanding of PSP. Objective To characterize the demographic, clinical, and phenotypic profiles of a large
Kukkle PL, Garg D, Ganguly J, Desai S, Kandadai RM, Mehta S, Wadia PM, Joshi D, Sahoo L, Paramanandam V, Reddy TAV, Mukherjee A, Krishnan S, Shetty K, Sankhla C, Agarwal P, Shah HS, Bhowmick S, Chandarana M, Venkata M, Geetha TS, Menon R, Charugulla S, Murugan S, Gupta R, Kumar N, Biswas A, Kumar H, Borgohain R, Morris H, Ramprasad VL, Parkinson's Research Alliance of India (PRAI) and the Global Parkinson's Genetic Program (GP2).   +31 more
europepmc   +2 more sources

Clinical features of progressive supranuclear palsy

Frontiers in Aging Neuroscience, 2023
BackgroundProgressive supranuclear palsy (PSP) is a clinically heterogenous atypical parkinsonian syndrome. Therefore, early recognition and correct diagnosis of PSP is challenging but essential.
Yafei Wen, Qijie Yang, Bin Jiao, Bin Jiao, Bin Jiao, Bin Jiao, Bin Jiao, Weiwei Zhang, Jingyi Lin, Yuan Zhu, Qian Xu, Qian Xu, Hui Zhou, Ling Weng, Ling Weng, Xinxin Liao, Yafang Zhou, Junling Wang, Jifeng Guo, Jifeng Guo, Jifeng Guo, Jifeng Guo, Xinxiang Yan, Xinxiang Yan, Xinxiang Yan, Xinxiang Yan, Hong Jiang, Beisha Tang, Beisha Tang, Beisha Tang, Beisha Tang, Lu Shen, Lu Shen, Lu Shen, Lu Shen, Lu Shen, Lu Shen   +36 more
doaj   +1 more source

Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease

NeuroImage: Clinical, 2016
Background: Advanced brain MR techniques are useful tools for differentiating Progressive Supranuclear Palsy from Parkinson's disease, although time-consuming and unlikely to be used all together in routine clinical work.
Stefano Zanigni, Giovanna Calandra-Buonaura, David Neil Manners, Claudia Testa, Dino Gibertoni, Stefania Evangelisti, Luisa Sambati, Maria Guarino, Patrizia De Massis, Laura Ludovica Gramegna, Claudio Bianchini, Paola Rucci, Pietro Cortelli, Raffaele Lodi, Caterina Tonon   +14 more
doaj   +1 more source

Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting

Clinical Parkinsonism & Related Disorders, 2020
Background and Purpose: The clinical diagnosis of progressive supranuclear palsy can be challenging, as the clinical presentation overlaps with that of Parkinson's disease and multiple system atrophy.
Jessica Cooperrider, Brent Bluett, Stephen E. Jones   +2 more
doaj   +1 more source

Pulmonary embolism: ′the great masquerader′ of pneumonia in a patient with progressive supranuclear palsy

The Egyptian Journal of Internal Medicine, 2016
Patients with Parkinson′s disease are at risk of developing aspiration pneumonia. Pulmonary embolism is a rare but life-threatening complication in such patients, but could the same be true in progressive supranuclear palsy, an atypical form of ...
Robin G Manappallil, Vinod Krishnan
doaj   +1 more source

Magnetic resonance imaging in the diagnosis of progressive supranuclear palsy: A case report and review of literature

Clinical Case Reports, 2023
Key Clinical Message Progressive supranuclear palsy (PSP) has many clinical features overlapping with other Parkinson syndromes and differentiation on clinical ground is difficult.
Baraka Alphonce, Francisca Komanya, Mbelwa Bitesigilwe, John R. Meda, Azan Nyundo   +4 more
doaj   +1 more source

Environmental Risk Factors for Progressive Supranuclear Palsy [PDF]

Journal of Movement Disorders, 2021
Typically, progressive supranuclear palsy (PSP) is clinically characterized by slow vertical saccades or supranuclear gaze palsy, levodopa-resistant parkinsonism with predominant axial symptoms, and cognitive executive impairment.
Hee Kyung Park, Sindana D. Ilango, Irene Litvan   +2 more
doaj   +1 more source

Procerus sign: Mechanism, clinical usefulness, and controversies

Annals of Indian Academy of Neurology, 2018
This sign is observed in atypical parkinsonism mainly in Progressive Supranuclear Palsy. The exact mechanism of this sign is not clear but the contraction of the Corrugator Supercilii muscle is the most important factor for the generation of vertical ...
Shakya Bhattacharjee
doaj   +1 more source